Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 2/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.37 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.33 |
| ▸ | CCR9 | P51686 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2221082 | 0.88 | ELOVL1 (0.38) | PRMT5WDR77CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL10283765 | 0.83 | RIPK1 (0.36) | GRM5 | |
| SCHEMBL10283764 | 0.83 | GRM5 (0.51) | GRM5 | |
| SCHEMBL10283766 | 0.82 | ALDH1A1 (0.41) | — | |
| SCHEMBL10283763 | 0.81 | FADS1 (0.38) | ELOVL1GRM5 | |
| SCHEMBL13274946 | 0.80 | KMT2A (0.40) | PRMT5WDR77CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13274537 | 0.80 | CHRNB2 (0.33) | PRMT5WDR77CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13275049 | 0.75 | ELOVL1 (0.38) | ELOVL1CHRM4 | |
| SCHEMBL15923836 | 0.75 | CHRNB2 (0.39) | PRMT5WDR77CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL13274585 | 0.73 | MTOR (0.45) | PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515657-A1 | TYROSINE KINASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | PRMT5 621/4885WDR77 1049/4885CHRNB2 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.